The San Francisco-based women’s health intelligence startup Collective X Health (CX) has emerged from stealth with a $3.2 million pre-seed funding round.
Council Capital and Anthemis Female Innovators Lab Fund co-led the pre-seed round with participation from SoGal Ventures, Emerson Collective, Muse Capital, and Segal Ventures.
Co-founded by exercise physiologist and nutrition scientist Dr. Stacy Sims, CEO Lindsey Abramo, and Chief Brand Officer Angelica Marden, Collective X is developing a business-to-business women’s health intelligence platform designed to help companies build health and performance products around research specific to female physiology, according to Forbes reports.
Its founding customers include Human Powered Health and Altra Running, which will license Collective X’s intelligence through an application programming interface, or API, to support health, performance, and recovery insights.
Collective X Health is not primarily a consumer-facing health app or wearable device. Instead, it provides the research-backed intelligence that other companies can use to inform their own technology and services.
The platform organizes peer-reviewed research and female-specific data into a structured knowledge base that businesses can access through an API. In practical terms, that connection allows a company’s existing software to access Collective X’s information and incorporate it into its own products.
Collective X Health has research and data partnerships with academic journals, Open Medicine Foundation, WildAI, and Eternal, a pipeline of more than 50 prospective partners. With fresh funds, Collective X Health plans to increase the depth of its research across every life stage and condition, expand its intelligence, rapidly scale early enterprise demand, and drive new research in women’s health.
Women’s health tech startups have secured billions of dollars so far in 2026. More recently, Women’s health startup Evvy has raised $40 million in a Series B funding round to build the datasets and AI infrastructure that precision medicine in women’s health has been missing.